Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
IPO Year: 2021
Exchange: NASDAQ
Website: movano.com
DEF 14A - Movano Inc. (0001734750) (Filer)
10-Q - Movano Inc. (0001734750) (Filer)
PRE 14A - Movano Inc. (0001734750) (Filer)
425 - Movano Inc. (0001734750) (Subject)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K/A - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
Fastest customizable press release news feed in the world
Shares Expected to Begin Trading on Split-Adjusted Basis on October 10, 2025 PLEASANTON, Calif., Oct. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on October 10, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Friday, October 10, 2025, and will continue to trade on The Nasdaq Capital Market under the symbol "MOVE." The new CUSIP number for the common stock will be 62459M 305.
PLEASANTON, Calif., Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that, by letter received on August 27, 2025, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to (i) the Company regaining compliance with Listing Rule 5250(c)(1), requiring the timely filing of periodic reports (the "Period Filing Rule"), by filing its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 on or before September 30, 2025, and (ii) the Company demonstrating compliance with Listing Rule 5550(a)(2), requiring the main
PLEASANTON, Calif., Aug. 22, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended June 30, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Filing Requirement") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on August 14, 2025.
Received Delisting Notice from Nasdaq Related to Minimum Bid Price Requirement and Late Filing of the Form 10-Q for the period ended March 31, 2025 PLEASANTON, Calif., July 11, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") announced today that, on July 7, 2025, it received a delisting determination from The Nasdaq Capital Market with respect to the $1.00 per share bid price requirement (the "Bid Price Requirement"), as set forth in Listing Rule 5550(a)(2), and the late filing requirement, as set forth in Listing Rule 5250(c)(1), given the delay in filing its Form 10-Q for the quarter ended March 31, 2025 (the "Filing Requirement")(together, the "Notice"). Accordingly, the
PLEASANTON, Calif., May 23, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)(the "Company") announced today that it received a notice (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that because the Company had not yet filed its Form 10-Q for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") requiring Nasdaq-listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Form 10-Q was due on May 15, 2025.
PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value. To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that this process will result in any transaction or other strategic change or as to the
Leveraging the Company's System-on-a-Chip (SoC), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (RF)-enabled blood pressure device PLEASANTON, Calif., April 22, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study. Movano Health's prototype demonstrated a level of accuracy well within the standards recognized by the FDA for blood pressure monitoring devices, achieving an overall mean absolute difference (MAD) of 4.9 mmHg, which significantly exceeds the 7 mmHg MAD threshold required per a standard for wea
Upgrades Also Include Integration with Apple Health, Manual Post-Workout Logging PLEASANTON, Calif., March 10, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology and maker of the Evie Ring, today announced a series of new data personalization, trend tracking and integration features on the ring's companion app that expand support for women's wellness journeys. The enhancements follow January's beta release of EvieAI, the first wearable-based virtual wellness assistant built exclusively with training data from medical journals. Available immediate
New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (NASDAQ:MOVE) announced today that it has commenced a blood pressure clinical trial with its newly developed cuffless blood pressure wrist wearable. The study, which is expected to include at least 70 participants and be completed during the second week of February, utilizes the updated device to monitor pulse pressure waveforms in comparison with a hospital grade blood pressure device. The new wearable will also collect data on a host of other vital signs including pulse rate, blood oxygen saturation (SpO2), respiration rate and ECG waveforms.
Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer health questions quickly, reliably and securely through the ring's companion app. Planned future integration with Evie data will allow EvieAI's responses to be p
Live finance-specific insights
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device
Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report second quarter 2024 financial and operating results on Wednesday, August 14, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The c
Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance processPlans launch of Evie Med and focuses on B2B opportunitiesPlans arterial blood pressure study for JuneConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., May 15, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update. Following the successful close of its recent $24 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device company, Movan
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., May 6, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The confere
Financing included a strategic seed investment by a tier-1 multi-billion dollar medical device company and participation from members of Movano Health's management team and board of directors Hosting conference call on April 4, 2024 at 2:00 PM PT/5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today has agreed to sell approximately 45 million units in a $24 million private placement, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dolla
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif., April 2, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET. Attendees can access the live webcast here or on the investors section of Movano Health's website at https://ir.movano.com. The con
PLEASANTON, Calif., Aug. 8, 2023 /PRNewswire/ -- Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it will report second quarter 2023 financial and operating results on Monday, August 14, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT (5:00 p.m. EDT). Attendees can access the live webcast here or on the investors section of Movano Health's webs
Conference call begins at 2:00 p.m. Pacific time today PLEASANTON, Calif., Nov. 14, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ:MOVE) dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update. Highlights from the third quarter and recent weeks include the following: Movano Health continues to expect to test the wearability and functionality of its smart device in beta programs with multiple strategic partners b
This live feed shows all institutional transactions in real time.
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G/A - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)